Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: dwight martin who wrote (18724)	4/6/1998 10:07:00 PM
From: Machaon	Read Replies (1) \| Respond to of 32384

<< Rather mentioned what I thought was Raloxifene >> Thanks. I think that you are correct about this. << Made it sound like something was going to happen with pretty quickly with the newer SERMs. >> Since the emphasis was on "newer" drugs, in the pipeline, I thought that it was a positive for Ligand. They certainly didn't spend the evening saying that Tamoxifen was the cure-all. In fact, there were more questions about the use of Tamoxifen, and side effects, than there were praises. I was kinda hoping that they would also mention drugs like Targretin, which was just recently compared to Tamoxifen in those naked, and "oh so ugly mice" tests. Regards, Bob

To: dwight martin who wrote (18724)	4/6/1998 10:08:00 PM
From: Henry Niman	Respond to of 32384

dwight, I just heard an NBC report. They did say Raloxifene which is LLY's Evista. It has already been approved for osteoporosis and I think that prevention trials have begun. PFE's Droloxifene has not been approved yet, but it is in Phase II trails for osteoporosis and just started a breast cancer prevention trail. PFE's CP-366,156 just began phase II for osteoporosis and AHP's TSE424 just started a Phase I trial for osteoporosis. As part of the LLY deal, LGND will be exploring using Targretin (or other rexinoids) with Evista (or other 2nd generation SERMs) for breast cancer (treatment and I assume prevention).